Clinuvel Pharmaceuticals Limited

Csl Limited

Michael John Kleinig

Thomas R Tice

Jay K Staas

Adrian Lee

Christopher Vincent Doidge

Ian George Barr

Jerry Kanellos

Kenneth B Kirby

Berno I Pettersson, Jr

Teresa Martinelli

Elizabeth Pietrzykowski

Fiona Jane Buck

Charles Alexander Quinn

Berno I Pettersson

Jr Berno I Pettersson

Described herein are methods and compositions for inducing melanogenesis in a human subject. The method comprises administering to a subject an alpha-MSH analogue, in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of subject without inducing homologous desensitization of the melanocortin-1 receptors.

Methods of inducing melanogenesis in a subject

Described herein are compositions comprising an alpha-MSH analogue and a transdermal delivery system and methods for inducing melanogenesis and/or preventing UV radiation-induced skin damage in a subject by topical administration of these compositions.

Compositions and methods for including melanogenesis in a subject

The present invention relates to methods for purifying fibrinogen. In one aspect, the present invention relates to a method of separating fibrinogen from plasma fraction I precipitate. In another aspect, the invention relates to the purification of fibrinogen using ion exchange chromatography.

Separation of fibrinogen from plasma proteases

An antigenic preparation for use in the treatment or prevention of Helicobacter infection in a mammalian host, comprises the lipopolysaccharide (LPS) of Helicobacter bacteria, particularly the LPS of or , or an immunogenic fragment thereof.

Antigenic preparation for treatment or prevention of helicobacter infection

Growing community of inventors

Brunswick, Australia

Michael John Kleinig